Real-world outcomes with elranatamab in multiple myeloma: a multicenter analysis from the U.S. Multiple Myeloma Immunotherapy Consortium - PubMed
3 hours ago
- #elranatamab
- #real-world outcomes
- #multiple myeloma
- Elranatamab showed an overall response rate of 65% and median progression-free survival of 4.3 months in a real-world cohort of 130 heavily pretreated multiple myeloma patients.
- A novel ALPS prognostic score, based on elevated LDH and low hemoglobin, stratified patients into distinct risk groups for outcomes such as overall survival and duration of response.
- Prior exposure to BCMA-targeted therapies reduced the depth of response, and patients treated within one year of prior therapy had inferior overall survival.
- Infections occurred in 38% of patients, with intravenous immunoglobulin supplementation associated with improved infection-free survival and progression-free survival.
- The real-world cohort was more heavily pretreated and frailer than clinical trial populations, with only 22% meeting eligibility for the MagnetisMM-3 trial.